Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer

Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, June 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of...

i-charging Receives Frost & Sullivan's 2025 European Competitive Strategy Leadership Award for Excellence in EV Ultra-fast and Megawatt Charging

i-charging Receives Frost & Sullivan's 2025 European Competitive Strategy Leadership Award for Excellence in EV Ultra-fast and Megawatt Charging

Recognized for delivering strategic innovation, advanced technology, and customer-focused solutions that redefine EV charging infrastructure across Europe SAN ANTONIO, June 3, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce that...

NSFOCUS Receives Frost & Sullivan's 2025 Asia-Pacific Competitive Strategy Leadership Award for Excellence in Anti-DDoS Protection

NSFOCUS Receives Frost & Sullivan's 2025 Asia-Pacific Competitive Strategy Leadership Award for Excellence in Anti-DDoS Protection

The company is being recognized for its technological innovation, customer-centric approach, and market-leading on-premises DDoS defense solutions across the Asia-Pacific cybersecurity landscape. SAN ANTONIO, June 3, 2025 /PRNewswire/ -- Frost &...

Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)

Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)

SHANGHAI, May 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Albipagrastim alfa for Injection (trade name: MAILISHENG, R&D code: 8MW0511) developed by its...

Gastops Receives Investment from RTX for Next Generation Monitoring Technologies

Gastops Receives Investment from RTX for Next Generation Monitoring Technologies

Investment made possible by Canadian Industrial and Technological Benefits Policy (ITB) OTTAWA, ON, May 29, 2025 /PRNewswire/ -- Gastops Ltd. is announcing a joint agreement under Canada's Industrial and Technology Benefits (ITB) policy for a...

CANGO Mobility Receives Frost & Sullivan's 2025 European Customer Value Leadership Award for Excellence in Telematics Solutions

CANGO Mobility Receives Frost & Sullivan's 2025 European Customer Value Leadership Award for Excellence in Telematics Solutions

CANGO is recognized for driving innovation and delivering customer-centric telematics solutions that optimize fleet performance, enhance connectivity, and support software-defined vehicle strategies. SAN ANTONIO, May 28, 2025 /PRNewswire/ -- Frost...

U Power Limited Receives "Beyond Impact Award" at the 5th BEYOND International Technology Innovation Expo in Macau

U Power Limited Receives "Beyond Impact Award" at the 5th BEYOND International Technology Innovation Expo in Macau

Beyond Impact Award recognizes companies with substantial contributions to the environment, society, economy, and technology, aligning with the UN's Sustainable Development Goals SHANGHAI, May 27, 2025 /PRNewswire/ -- U Power Limited (Nasdaq: UCAR)...

ZYLOX Unicorn™ Vascular Closure Device Receives Regulatory Approval in Indonesia

ZYLOX Unicorn™ Vascular Closure Device Receives Regulatory Approval in Indonesia

HANGZHOU, China, May 27, 2025 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. ("Zylox-Tonbridge" or the "Company") today announced that its proprietary ZYLOX Unicorn™ Vascular Closure Device (VCD) has received regulatory approval in...

Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC

Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC

SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from...

Eason Technology Limited Receives Notification from NYSE Regarding Delayed Form 20-F Filing

Eason Technology Limited Receives Notification from NYSE Regarding Delayed Form 20-F Filing

HONG KONG, May 23, 2025 /PRNewswire/ -- Eason Technology Limited ("Eason Technology" or the "Company") (NYSE: DXF) today announced that it received a notice from NYSE Regulation indicating that the Company is not in compliance with the continued...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • menu
    menu